Company news
Shanghai Pharmaceuticals Holding Co. Ltd. news in 2025
Shanghai Pharmaceuticals Holding Co. Ltd.'s news releases, calls and decks from 2025, newest first.
Acquisition Report
December 30, 2025
Announcement on Resolutions of the 27th Meeting of the 8th Board of Directors
December 29, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
December 24, 2025
Indicative Announcement on Restricted Exercise Period for the 3rd Exercise Period of the Reserved Stock Options of 2019 A-share Stock Option Incentive Plan
December 18, 2025
Announcement on Obtaining Philippine Drug Registration Certificate for Hydroxychloroquine Sulfate Tablets
December 15, 2025
Announcement on the Approval of the Marketing Authorization Application for Sitagliptin Fumarate Tablets (SPH3127 Tablets)
December 10, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
December 9, 2025
Announcement on Amisulpride Orodispersible Tablets Passing the National Medical Insurance Negotiation and Being Successfully Included in the National Medical Insurance Catalog
December 8, 2025
Announcement on the Termination of the Cooperation Agreement with Guizhou Shenuo Biotechnology Co., Ltd.
December 5, 2025
Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2025
November 28, 2025
上海医药集团股份有限公司关于召开2025年第二次临时股东大会的通知
November 18, 2025
Announcement on Approval of Eslicarbazepine Acetate Tablets by the U.S. FDA
November 10, 2025
Announcement on Obtaining Approval for Production of Tofacitinib Citrate Sustained-Release Tablets
November 6, 2025
Announcement on Resolutions of the 25th Meeting of the 8th Board of Directors
October 30, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 28, 2025
Announcement on the Subsidiary Becoming the Marketing Authorization Holder of Amisulpride Orally Disintegrating Tablets
October 24, 2025
Announcement on Obtainment of U.S. FDA Approval for Doxycycline Capsules
October 14, 2025
Announcement on Independent Exercise Results of Reserved Stock Options in the 3rd Vesting Period of 2019 A-share Stock Option Incentive Plan and in Q3 2025
October 9, 2025
Announcement on Resignation of Senior Management Members
September 25, 2025
Indicative Announcement on Changes in Shareholder's Equity
September 22, 2025
Announcement on Nicorandil Tablet Passing Generic Drug Consistency Evaluation
September 18, 2025
Announcement on Shareholding Increase Plan for the Controlling Shareholder
September 15, 2025
Announcement on Obtaining Philippine Drug Registration Certificate for Aripiprazole Tablets
September 12, 2025
Announcement on Diprophylline Injection Passing Generic Drug Consistency Evaluation
September 4, 2025
Announcement on Verapamil Hydrochloride Injection Passing Generic Drug Consistency Evaluation
September 1, 2025
2025 Semi-annual Report
August 28, 2025
Announcement on Obtaining Philippine Drug Registration Certificate for Oxytocin Injection and Octreotide Acetate Injection
August 22, 2025
Announcement on the Receipt of Clinical Trial Approval Notice for a New Indication of B019
July 29, 2025
Announcement on Salbutamol Sulfate Injection Passing Generic Drug Consistency Evaluation
July 28, 2025
Announcement on Acquisition of 10% Equity of SIIC Finance Co., Ltd. and Related Party Transactions
July 25, 2025